We’ve always been fans of lateral thinking, the Edward de Bono way – so we love Ilya Pharma. Thei ILP-technology is based on deploying chemokines, which until now have been regarded as being too instable and having too short a half-life in tissue to be effective in major wounds. However, with ILP100, the lactic acid bacteria functions as small bioreactors on site in the wound, continuously introducing the CXCL12 into the wound tissue for a transient time coverage. https://www.ilyapharma.se